Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment

Objective: Morbid obesity may be related to a prolactinoma, although uncommon, and can lead to adverse effects like insulin resistance and metabolic syndrome. Recent research suggests that hyperprolactinemia causes an abnormal lipid profile, weight gain, and cardiovascular diseases. Moreover, high p...

Full description

Bibliographic Details
Main Authors:	Muzaffar Ali, MBBS, Lubna Mirza, MD
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	AACE Clinical Case Reports
Subjects:	dopamine agonist endocrinology morbid obesity prolactinoma weight loss
Online Access:	http://www.sciencedirect.com/science/article/pii/S2376060521000134

Similar Items

Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
by: Irena A. Ilovayskaya, et al.
Published: (2023-12-01)

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
by: Hao Tang, et al.
Published: (2021-03-01)

Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy
by: Linjie Wang, et al.
Published: (2023-11-01)

Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy
by: Lukas Andereggen, et al.
Published: (2024-03-01)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
by: Sarah Byberg, et al.
Published: (2019-10-01)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
by: Sunita M C De Sousa
Published: (2023-01-01)

Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight
by: S. Caprio, et al.
Published: (2024-06-01)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
by: Yunzhi Zou, et al.
Published: (2021-11-01)

Current and Perspective Approaches to the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2023-07-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)

Prolactinomas: evolution after menopause
by: Maria Susana Mallea-Gil, et al.

The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
by: Larisa Dzeranova, et al.
Published: (2016-11-01)

Operative treatment of cystic prolactinomas: a retrospective study
by: Weijie Su, et al.
Published: (2023-05-01)

Pathogenesis, diagnosis and current treatment of prolactinoma: a review of the literature
by: Monika Szyszka, et al.
Published: (2024-07-01)

Treatment of Prolactinoma
by: Warrick J. Inder, et al.
Published: (2022-08-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
by: Shuman Wang, et al.
Published: (2021-11-01)

Prolactinoma - which patients react favorably to cabergoline medication?
by: Karatas Savas, et al.
Published: (2022-10-01)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
by: Xiaoan Ke, et al.
Published: (2022-04-01)

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline
by: Bassam M Flamerz Arkawazi
Published: (2020-01-01)

The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
by: Zilya A. Kalmykova, et al.
Published: (2019-09-01)

Second attempt of Cabergoline withdrawal in patients with prolactinomas after a failed first attempt : is it worthwhile?
by: Lucio eVilar, et al.
Published: (2015-02-01)

Prolactinomas in adolescent and elderly patients—A comparative long-term analysis
by: Lukas Andereggen, et al.
Published: (2023-02-01)

Unusual Course of an Aggressive Pituitary Prolactinoma: Case Report and Review of the Literature
by: Juliana Pérez Pinzón, et al.
Published: (2019-04-01)

The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
by: Laurent Vroonen, et al.
Published: (2023-08-01)

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
by: Annabelle G Hayes, et al.
Published: (2023-01-01)

Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
by: Grzegorz Zielinski, et al.
Published: (2020-07-01)

Commentary: “Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery”
by: Lukas Andereggen, et al.
Published: (2021-05-01)

Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma
by: TAN Huiwen, LI Danting, YU Yerong
Published: (2024-02-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01)

Dopamine-Agonist Induced Cerebrospinal Fluid Rhinorrhea; a Case Report
by: Hira Irfan, et al.
Published: (2021-01-01)

TRANSSPHENOIDAL SURGERY OF NASAL LIQUORRHEA AS A COMPLICATION AFTER TREATMENT OF PROLACTINOMAS WITH DRUGS
by: A. V. Polezhaev, et al.
Published: (2018-06-01)

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors
by: Galina Afanas'evna Melnichenko, et al.
Published: (2015-04-01)

Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
by: José Miguel Hinojosa-Amaya, et al.
Published: (2020-10-01)

Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center
by: Aram Yang, et al.
Published: (2020-08-01)

Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
by: Lucio Vilar, et al.

Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas
by: Markus Huber, et al.
Published: (2022-02-01)

Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
by: Cristina Laguna Benetti-Pinto, et al.
Published: (2024-06-01)